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Abstract Tripeptidyl peptidase I (TPP-I) is a lysosomal
enzyme that cleaves tripeptides from the N-terminus of polypep-
tides. A comparison of TPP-I amino acid sequences with
sequences derived from an EST database suggested that TPP-I
is identical to a pepstatin-insensitive carboxyl proteinase of
unknown specificity which is mutated in classical late infantile
neuronal ceroid lipofuscinosis (LINCL), a lysosomal storage
disease. Both TPP-I and the carboxyl proteinase have an Mr of
about 46 kDa and are, or are predicted to be, resistant to
inhibitors of the four major classes of proteinases. Fibroblasts
from LINCL patients have less than 5% of the normal TPP-I
activity. The activities of other lysosomal enzymes, including
proteinases, are in the normal range. LINCL fibroblasts are also
defective at degrading short polypeptides and this defect can be
induced in normal fibroblasts by treatment with a specific
inhibitor or TPP-I. These results suggest that the cell damage,
especially neuronal, observed in LINCL results from the
defective degradation and consequent lysosomal storage of small
peptides.
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1. Introduction
Tripeptidyl peptidase I (TPP-I) is a lysosomal enzyme that
removes tripeptides from the amino-terminus of peptides [1^
4]. It is structurally and genetically unrelated to tripeptidyl
peptidase II, a cytoplasmic enzyme with a similar action
which is a member of the subtilisin class of serine proteases
[5]. TPP-I is unusual in that it is not inhibited by any of the
classical inhibitors of serine, cysteine, aspartate or metallopro-
teases [4]. TPP-I is potently inhibited by chloromethylketone
analogues of tripeptidyl substrates but the kinetics of inhib-
ition are not consistent with the enzyme being a serine or
cysteine proteinase [4]. The enzyme has an Mr of 46 kDa
and has a ubiquitous distribution in mammalian tissues.
TPP-I acts on small peptides in vitro, e.g. angiotensins and
glucagon, which are completely degraded to tripeptides, but
appears to be inactive on proteins, e.g. casein [4]. There is also
evidence for a tripeptidyl peptidase activity in hepatic endo-
somes which contributes to the degradation of glucagon [6].
TPP-I has previously been reported to degrade synthetic col-
lagen-like polymers producing Gly-Pro-X triplets which can
be further degraded by dipeptidyl peptidases and dipeptidase
[2]. Inhibitors of TPP-I inhibit bone resorption (where type I
collagen is the major protein being degraded) in an in vitro
assay suggesting that TPP-I contributes to protein turnover in
some physiological situations [3,4].
Recently, the N-terminal sequence and two internal sequen-
ces of rat spleen TPP-I have been reported [4]. Searching of
these sequences against an expressed sequence tag (EST) data-
base identi¢ed human and mouse ESTs which contained the
homologues of all three rat sequences. Sequencing of these
ESTs demonstrated that they contained full length clones
and that the sequence of the human clone is identical to
that of a recently identi¢ed lysosomal pepstatin-insensitive
carboxyl proteinase [7]. This enzyme shows homology to a
family of bacterial pepstatin-insensitive carboxyl proteinases
[8,9] but it is the only known eukaryotic member of this fam-
ily and its function is unknown.
Mutations in this pepstatin-insensitive carboxyl proteinase
have been identi¢ed in classical late infantile neuronal ceroid
lipofuscinosis, a lysosomal storage disease (LINCL, CLN2)
[7]. The neuronal lipofuscinoses are a heterogeneous group
of diseases associated with progressive neurodegeneration,
blindness and musculo-skeletal defects in infants and young
children [10]. In classical LINCL, death occurs around the age
of 10 when there is a dramatic decrease in the number of
neuronal cells. Other brain cell types are diminished in num-
ber and contain cytoplasmic (lysosomal) vacuoles ¢lled with
£uorescent lipopigment. Similar inclusions are observed in
many di¡erent cell types and in most other tissues although
cell viability is not as dramatically reduced [11]. We now show
that ¢broblasts which have been demonstrated to have muta-
tions in the pepstatin-insensitive carboxyl proteinase gene are
de¢cient in TPP-I activity.
2. Materials and methods
2.1. Sequencing of EST clones
Amino-terminal and internal sequences of rat spleen TPP-I [4] were
searched against an EST database (dbEST). A single human EST
clone (EST T7210) containing the human homologues of both internal
sequences was identi¢ed. The sequence of this EST was used to search
dbEST and clones overlapping both 5P and 3P ends were identi¢ed.
Further iterative dbEST searching of these and subsequent overlap-
ping EST clones allowed a 1500 bp contiguous sequence to be built
up. This composite sequence was used to perform a BLAST search of
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a non-redundant nucleotide database. The largest human and mouse
EST clones identi¢ed were AA287343 and AA119072 respectively and
these were sequenced in their entirety using 328M13 rev2 ET and
oligo-dT(20). Internal sequencing primers were designed using the
Human Genome Mapping Project (HGMP) Staden sequence process-
ing package primer design routine, from sequences obtained. ESTs
were obtained from HGMP, Hinxton, Cambridge, UK. Sequencing
was performed with the ABI Prism Big Dye Terminator Cycle Se-
quencing Ready Reaction Kit using an automated sequencer (PE
Applied Biosystems, model 377 XL). Alignment of sequences was
performed using PILEUP and calculations of homologies using
GAP (EGCG package at HGMP, Hinxton, Cambridge).
2.2. Cell culture
Two normal human skin ¢broblast cell lines (H1 and H2, males
aged 5 and 18 years) were obtained from The Heart Science Centre,
Hare¢eld Hospital and two from The Montreal Children’s Hospital
(MCH65 and MCH75, female 3.5 years and male 8 years). The
LINCL ¢broblasts used were WG0305 and WG0308 (female 7 years
and male 5.5 years, Montreal Children’s Hospital) and GM09404
(female, Coriell Cell Repository, Camden, NJ). Batten and Tay-Sachs
disease ¢broblasts (WG0277 and WG0312, male 5.5 years and female
5 years respectively) were also obtained from The Repository for
Mutant Human Cell Strains, The Montreal Children’s Hospital, Mon-
treal, Quebec, Canada. Cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% foetal bovine serum. Cells
were used for enzyme assays three passages after receipt (passages
12^15).
2.3. Enzyme assays
Cells were washed with phosphate bu¡ered saline, harvested by
scraping and homogenised in 50 mM sodium acetate pH 4.0/0.1%
Triton X-100 in a Dounce homogeniser. Fluorimetric assays for
TPP-I, cathepsins B and L, aminopeptidase and L-galactosidase, using
Ala-Ala-Phe-NHMec, CBZ-Phe-Arg-NHMec, Phe-NHMec and meth-
ylumbelliferyl-L-D-galactopyranoside as substrates, were carried out as
described previously [3,12,13]. Proteinase assays were performed using
FITC-casein or FITC-gelatin as substrates [14]. The £uorescamine
procedure was used to determine protein concentrations [15]. A Hi-
tachi F-2000 £uorimeter was used for £uorescence measurements.
To investigate the degradation of peptides by normal and LINCL
¢broblasts, cells were homogenised in 100 mM sodium acetate pH 4.0,
frozen and thawed three times and treated with protease inhibitors (1
WM E-64/1 mM PMSF/5 Wg/ml pepstatin and 2.5 mM EDTA or addi-
tionally with 1 WM AAF-CMK) and incubated with 500 Wg of peptide
for 16 h. The reaction was stopped by adding tri£uoroacetic acid
(TFA) to 0.1% and analysed by reversed phase HPLC using a Dyna-
max C18-300 column (4.6U250 mm) and a 0^40% acetonitrile/0.1%
TFA gradient over 60 min. Peaks were collected and analysed by
amino acid analysis [16].
3. Results and discussion
Four lines of evidence suggest that TPP-I is the enzyme
which is mutated in classical LINCL. Firstly, the partial se-
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Fig. 1. Alignment of human and mouse TPP-I deduced amino acid sequences and the N-terminal (ratnterm) and two internal (ratint1 and rat-
int2) sequences of rat TPP-I obtained by direct sequencing. Heavy shading denotes identical amino acids and light shading similar amino acids.
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quences of rat TPP-I are highly homologous to the deduced
sequence of the protein mutated in LINCL. Secondly, ¢bro-
blasts from LINCL patients are de¢cient in TPP-I activity.
Thirdly, there is speci¢c loss of acidic TPP activity whereas
alkaline TPP activity remains normal. Fourthly, LINCL ¢bro-
blasts are defective in their ability to degrade small peptides
and this de¢ciency can be induced in normal cells by a speci¢c
inhibitor of TPP-I.
3.1. Comparison of TPP-I and pepstatin-insensitive carboxyl
proteinase sequences
The amino acid sequences of the N-terminus and two in-
ternal peptides of rat spleen TPP-I were searched against
dbEST and a single EST clone containing potential human
homologues of both internal sequences was obtained. The
sequence of this EST was used to search dbEST and several
clones overlapping both 5P and 3P ends were obtained and
partially sequenced. The largest of these (AA287343, 2.7 kb)
was sequenced in its entirety and found to contain the full
coding sequence for a putative pepstatin-insensitive carboxyl
proteinase which is mutated in the lysosomal storage disease,
LINCL [7]. Similar searches identi¢ed a mouse EST
(AA119072) which contained the full coding sequence of a
mouse homologue (Fig. 1). Alignment of the deduced amino
acid sequences indicated that they were 89% identical and 91%
similar. The overall identity between the rat and human ami-
no acid sequences was 83% and between the rat and mouse
sequences, the identity was 89%. The mouse EST contained an
open reading frame of 1617 nucleotides with an ATG trans-
lation initiation codon 84 nucleotides 3P of the human initia-
tion codon. This would result in the loss of 29 amino acids at
the N-terminus. The nucleotide sequence indicates an inser-
tion of two nucleotides into a putative ATG start codon lo-
cated in the same position as the start of the human open
reading frame to give ATGTG. Correcting for this insertion
and the resulting frame shift would give a sequence encoding a
full length amino acid sequence homologous to that of the
human sequence. In two of the LINCL cell lines used in
this study, a single base substitution converts Cys365 to either
Tyr (WG0305) or Arg (WG0308) [7]. The sequence and struc-
tural organisation of the gene (CLN2) have now been deter-
mined [17].
Both TPP-I and the protein that is mutated in LINCL have
an Mr of 46 kDa [4]. Homology searching revealed that the
LINCL protein is related to a family of bacterial pepstatin-
insensitive carboxyl proteinases [7^9]. These enzymes di¡er
from other carboxyl (aspartate) proteinases in having an as-
partate and a glutamate rather than two aspartates in the
active site. The LINCL protease is the only known eukaryotic
member of this family of proteolytic enzymes. The inability of
serine, cysteine, aspartate and metalloproteinase inhibitors to
inhibit TPP-I is now easily explained.
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Fig. 2. pH optima of TPP activity in normal and LINCL ¢bro-
blasts. Homogenates of normal (MCH65) (E) and LINCL
(WG0308) (b) ¢broblasts were incubated with Ala-Ala-Phe-NHMec
over the pH range 3^9 and the liberated aminomethylcoumarin
measured £uorimetrically. The bu¡ers used were 0.1 M sodium cit-
rate (pH 3^4), 0.1 M sodium acetate (pH 4^6) and 0.1 M sodium
phosphate (pH 6^9) containing 0.5 M NaCl.
Table 1
Enzyme activities in normal and mutant ¢broblasts
Cell line Descrip-
tion
Speci¢c activity (units/mg protein)U1032 Relative speci¢c
activity
TPP-I AAF-CMK-
sensitive TPP-I
protease inhibitor-
resistant TPP-I
amino-
peptidase
cathepsin
B/L
L-galac-
tosidase
pepstatin-
insensitive
acid proteinase
H1 normal 1.34 þ 0.08
(103)
1.11 þ 0.04
(105)
1.36 þ 0.12
(101)
0.27 þ 0.04
(113)
18.4 þ 1.2
(106)
3.17 þ 0.27
(126)
92 þ 8
H2 normal 1.42 þ 0.05
(109)
1.17 þ 0.09
(110)
1.40 þ 0.10
(104)
0.23 þ 0.04
(96)
14.7 þ 0.8
(85)
3.33 þ 0.22
(133)
97 þ 12
MCH 65 normal 1.30 þ 0.07
(100)
1.06 þ 0.02
(100)
1.34 þ 0.07
(100)
0.24 þ 0.02
(100)
17.3 þ 1.1
(100)
2.51 þ 0.18
(100)
100 þ 9
MCH 75 normal 1.28 þ 0.03
(98)
1.01 þ 0.05
(95)
1.41 þ 0.10
(105)
0.27 þ 0.05
(113)
20.1 þ 1.3
(116)
2.87 þ 0.19
(114)
145 þ 14
WG 0277 Batten
disease
1.56 þ 0.07
(120)
1.35 þ 0.09
(128)
1.58 þ 0.13
(118)
0.20 þ 0.02
(83)
15.4 þ 0.6
(89)
3.02 þ 0.22
(120)
127 þ 11
WG 0312 Tay-Sachs 1.36 þ 0.06
(105)
1.20 þ 0.11
(113)
1.39 þ 0.12
(104)
0.16 þ 0.02
(67)
20.1 þ 0.9
(116)
3.42 þ 0.20
(136)
122 þ 13
WG 0305 LINCL 0.07 þ 0.01
(5)
0.06 þ 0.01
(6)
0.06 þ 0.01
(5)
0.30 þ 0.04
(125)
19.5 þ 1.1
(113)
3.79 þ 0.14
(151)
110 þ 10
WG 0308 LINCL 0.03 þ 0.01
(2)
0.03 þ 0.01
(3)
0.03 þ 0.01
(2)
0.27 þ 0.04
(113)
18.2 þ 1.3
(105)
3.42 þ 0.17
(136)
120 þ 11
GM 0904 LINCL 0.04 þ 0.01
(3)
0.04 þ 0.01
(4)
0.04 þ 0.01
(3)
0.30 þ 0.03
(125)
18.8 þ 0.7
(109)
3.28 þ 0.16
(131)
86 þ 9
Results are the means þ S.E.M. of ¢ve determinations (TPP-I assays) or three determinations (other activities). Numbers in parentheses are the
values normalised to MCH = 100. Casein was used as the substrate for the acid proteinase assays. The relative speci¢c activity for the acid
proteinase measurements was obtained by dividing the £uorimeter reading by the protein content and normalising the readings to MCH 65 = 100.
D.J. Vines, M.J. Warburton/FEBS Letters 443 (1999) 131^135 133
3.2. Lysosomal enzyme activities in LINCL ¢broblasts
Homogenates prepared from four normal and three LINCL
¢broblast cell lines were assayed for several lysosomal enzyme
activities (Table 1). As further controls, homogenates pre-
pared from Tay-Sachs disease (an unrelated lysosomal storage
disease) and Batten disease (juvenile neuronal ceroid lipofus-
cinosis) ¢broblasts were also assayed. There is a dramatic
reduction in TPP-I activity in the three LINCL ¢broblast
cell lines. Activities ranged from about 2 to 6% of those of
normal, Tay-Sachs and Batten disease ¢broblasts. A similar
result was obtained when the assays were carried out in the
presence of protease inhibitors. A more precise determination
of TPP-I activity, i.e. TPP-I activity sensitive to inhibition by
AAF-CMK, gave an identical result. The TPP-I substrate
(Ala-Ala-Phe-NHMec) may also be a substrate for aminopep-
tidases. However, aminopeptidase activity was similar in all
the cell lines. Two other lysosomal enzyme activities in
LINCL ¢broblasts, cathepsin B/L and L-galactosidase, were
also similar to those of normal cells. Homogenates of brain
tissue from LINCL patients have been reported to be de¢cient
in an acidic pepstatin-insensitive proteinase active on haemo-
globin [7]. Using casein as a substrate, we were unable to
detect any di¡erences in pepstatin-insensitive protease activity
between normal and LINCL ¢broblasts. No activity against
gelatin was observed in normal or LINCL ¢broblasts. This is
in agreement with our previous results which suggest that
TPP-I has little activity on proteins although the size limit
of its activity is unknown [4]. However, peptidases are able
to synergise with proteinases in the degradation of proteins
[18] and the extent of this synergy may be tissue dependent. If
TPP-I acts synergistically with other proteolytic enzymes, the
greatest e¡ect might occur in brain as most of the tissue dam-
age in LINCL patients is observed in this tissue.
Patients with Batten disease have similar symptoms to those
with LINCL but with a later onset. The nature of the material
stored within the lysosomes is also similar in the two diseases.
The function of the gene involved in Batten disease is un-
known [19]. TPP-I activities are normal in Batten disease ¢-
broblasts and it therefore seems unlikely that the product of
the Batten disease gene is involved in the transport or proc-
essing of TPP-I.
3.3. pH optima of TPP-I activity in normal and LINCL
¢broblasts
There were two distinct pH optima for TPP activity in
normal ¢broblasts at pHs 4.5 and 7 (Fig. 2). The activity at
pH 7 was about ¢ve times the activity at pH 4.5. The acidic
TPP activity was totally absent from LINCL ¢broblasts
whereas the activity at pH 7 was similar to that in normal
cells. The acidic TPP activity was resistant to inhibition by
inhibitors of serine (PMSF), cysteine (E-64), aspartate (pep-
statin) and metalloproteinases (EDTA) but was inhibited by
AAF-CMK suggesting that this activity is TPP-I. The TPP
activity at pH 7 was partially inhibited by all the inhibitors
suggesting that it results from the action of several peptidases.
This experiment provides further evidence for the speci¢c loss
of an acidic TPP activity in LINCL ¢broblasts.
3.4. Degradation of peptides by normal and LINCL ¢broblasts
TPP-I is capable of degrading short peptides to tripeptides
[4]. To investigate if the degradation of peptides is impaired in
LINCL cells, homogenates from normal and LINCL ¢bro-
blasts were incubated with a model, test peptide (NFAAQY-
DEKGVGLGPGN-H2, the N-terminal telopeptide of the K2
chain of type I collagen), the reaction products separated by
reversed phase HPLC and characterised by amino acid anal-
ysis (Fig. 3). Two major reaction products were observed
when the telopeptide was incubated with a normal cell homo-
genate (Fig. 3A). The peptide eluting after 40 min was iden-
ti¢ed as AQYDEKGVGLGPG-NH2, the telopeptide with the
three N-terminal amino acids removed, and the peptide elut-
ing after 28 min as DEKGVGLGPG-NH2, the telopeptide
with the six N-terminal amino acids removed. It is likely
that the telopeptide has been subjected to the sequential re-
moval of N-terminal tripeptides. Neither of the two degrada-
tion products was observed when the telopeptide was incu-
bated with extracts or LINCL ¢broblasts (Fig. 3B). These
incubations were carried out in the presence of PMSF, E-
64, EDTA and pepstatin. When the normal ¢broblast extract
was additionally treated with AAF-CMK, a speci¢c inhibitor
of TPP-I in these cells, before incubation with the telopeptide,
the appearance of both degradation products was greatly re-
duced (Fig. 3C). Thus, inhibition of TPP-I in normal ¢bro-
blasts and mutations in the LINCL gene produce a similar
defect in the degradation of short peptides. This result is con-
sistent with TPP-I being the enzyme which is mutated in
LINCL.
About 60% of the material stored within lysosomes in
LINCL is believed to be protein. An unusual feature of the
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Fig. 3. Degradation of telopeptide-2 by normal and LINCL ¢bro-
blasts. Homogenates of normal (MCH65) and LINCL (WG0308) ¢-
broblasts were incubated with 500 Wg of telopeptide-2 for 16 h at
37‡C at pH 4 (100 mM sodium acetate) after the addition of 1 mM
PMSF, 1 WM E-64, 5 Wg/ml pepstatin and 2.5 mM EDTA. Reac-
tions were stopped by adding TFA to 0.1% and analysed by re-
versed phase HPLC using a Dynamax C18-300 column (4.6U250
mm) and a 0^40% acetonitrile/0.1% TFA gradient over 60 min.
Peaks were collected and analysed by amino acid analysis. A:
MCH65 digest, peak I is DEKGVGLGPG-NH2, peak II is AQY-
DEKGGLGPG-NH2 and peak III NFAAQYDEKGVGLGPG-NH2
(undigested telopeptide-2). B: WG0308 digest, note the absence of
peaks I and II. C: MCH65 digest treated with AAF-CMK prior to
the digestion, peaks I and II are greatly reduced. D: Telopeptide-2
added to the MCH65 reaction mixture at the end of the 16 h diges-
tion.
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storage material in LINCL is that a major component is sub-
unit c of mitochondrial ATP synthase [20,21]. Subunit c is a
small (Mr 7600 kDa), very hydrophobic protein. Its accumu-
lation in LINCL cells has been clearly shown to result from a
reduced rate of degradation rather than increased synthesis
and normal ¢broblasts contain a proteolytic activity which
can degrade the subunit c stored within the lysosomes of
LINCL ¢broblasts [22]. It will be interesting to determine if
TPP-I has any activity on subunit c. However, subunit c ac-
cumulation is also observed in Batten disease and certain un-
related lysosomal storage diseases suggesting that it may be a
non-speci¢c response to the lysosomal storage of other mate-
rial [23]. Our results support the suggestion of Sleat et al. [7]
that LINCL results from defects in a proteolytic enzyme in-
volved in the degradation of peptides especially those acting
on neurones. Recently, TPP-II has been identi¢ed as the en-
zyme which inactivates the neuropeptide cholecystokinin pos-
sibly regulating signalling pathways associated with this pep-
tide [24]. Elucidating the role of TPP-I in the metabolism of
neurone-speci¢c peptides might enhance our understanding of
the disease process in LINCL.
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